Catalyst Pharmaceuticals (CPRX) Competitors

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends, valuation and community ranking.

Which has better earnings & valuation, CPRX or ASND?

Catalyst Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$491.73M	6.02	$71.41M	$1.31	18.54
Ascendis Pharma A/S	$363.64M	28.58	-$409.12M	-$7.10	-24.01

Do analysts prefer CPRX or ASND?

Catalyst Pharmaceuticals currently has a consensus price target of $32.29, indicating a potential upside of 32.92%. Ascendis Pharma A/S has a consensus price target of $204.67, indicating a potential upside of 20.08%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Catalyst Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.93

Do insiders and institutionals hold more shares of CPRX or ASND?

79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Which has more volatility and risk, CPRX or ASND?

Catalyst Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.

Does the MarketBeat Community prefer CPRX or ASND?

Catalyst Pharmaceuticals received 56 more outperform votes than Ascendis Pharma A/S when rated by MarketBeat users. Likewise, 75.11% of users gave Catalyst Pharmaceuticals an outperform vote while only 66.87% of users gave Ascendis Pharma A/S an outperform vote.

Company	Underperform	Outperform
Catalyst Pharmaceuticals	Outperform Votes 504 75.11%	Underperform Votes 167 24.89%
Ascendis Pharma A/S	Outperform Votes 448 66.87%	Underperform Votes 222 33.13%

Is CPRX or ASND more profitable?

Catalyst Pharmaceuticals has a net margin of 31.01% compared to Ascendis Pharma A/S's net margin of -104.54%. Catalyst Pharmaceuticals' return on equity of 40.79% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	31.01%	40.79%	34.87%
Ascendis Pharma A/S	-104.54%	N/A	-39.23%

Does the media refer more to CPRX or ASND?

In the previous week, Catalyst Pharmaceuticals and Catalyst Pharmaceuticals both had 12 articles in the media. Catalyst Pharmaceuticals' average media sentiment score of 1.60 beat Ascendis Pharma A/S's score of 1.26 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Catalyst Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Ascendis Pharma A/S	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Catalyst Pharmaceuticals beats Ascendis Pharma A/S on 15 of the 18 factors compared between the two stocks.